



Licensing Opportunity

Phosphospecific monoclonal antibodies against human C5a Receptor

Scientists at the Georg-August-University Göttingen produced different monoclonal antibodies directed against phosphorylation sites of C5aR. Using these antibodies the activation state of C5aR can be directly measured in tissue or cultured cells. Since the relevant epitope is known to be phosphorylated by Protein Kinase C (PKC), this principle can also be used to measure PKC activity or to screen for new PKC inhibitors. CD88 is expressed by peripheral blood granulocytes and monocytes. Binding of C5a (fragment of the complement factor C5) to CD88 leads to cellular activation, including chemotaxis.

Available Clones for Licensing

Clone Name	Isotype	Ig Yield [µg/ml]	Epitope	Applications	Functional properties	Reference
32G-1	IgG1/k	Medium: 27 Bioreactor: 300	Phosphorylated human C5aR-CT (phosphoSer-334)	WB,IF,E	Reacts only with C5a-activated, PKC-phosphorylated C5aR	Pollok-Kopp et al., <i>Immunobiol</i> 208:123 (abstract)
P12/1	IgG1/k	N.A.	Human C5aR-NT (Met1-Asn31)	WB,F,IH		Oppermann et al, <i>J.Immunol.</i> 1993 151:3785-94
S5/1	IgG2a/k	N.A.	Human C5aR-NT (Asp15-Asp27)	WB,F,E, FN,IP	Blocks C5a binding to C5aR	Oppermann et al, <i>J.Immunol.</i> 1993 151:3785-94
W17/1	IgG1/k	N.A.	Human C5aR-NT (Asp15-Asp27)	F,E		Oppermann et al, <i>J.Immunol.</i> 1993 151:3785-94
R63	IgG1/k	N.A.	Rat C5aR-NT (Met1-Asp38)	F,IH	(Does not block C5a binding)	Schlaf et al, <i>Lab Invest.</i> 79:1287-97

(N.A.: Information not available; WB: Western blotting; E: ELISA; F: flow cytometry; FN: functional studies; IP: immunoprecipitation; IH: immunohistochemistry on cryostat sections)

All hybridoma clones were derived from the fusion of murine splenocytes with X63Ag8.653 myeloma cells and secrete significant amounts of antibodies when grown in 80:20–10 medium (80 parts RPMI 1640, 20 parts medium 199, supplemented with 10% heat-inactivated fetal bovine serum, penicillin (100 units/ml), 100 g/ml streptomycin, hypoxanthine/thymidine (optional), recombinant human Interleukin-6 (20U/ml)

We are looking for companies, who are interested in **licensing** these antibodies for selling them to industrial and scientific institutions or for developing advanced **diagnostic tests** and **therapeutic solutions**.